Rosuvastatin Market Estimated to Grow at A CAGR of 3.7% to 2026: Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis), Lupin Ltd., Hetero Drugs Ltd., Biocon Ltd., Cadilla Pharmaceuticals, Aurobindo Pharmaceuticals
Rosuvastatin Market Estimated to Grow at A CAGR of 3.7% to 2026: Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis), Lupin Ltd., Hetero Drugs Ltd., Biocon Ltd., Cadilla Pharmaceuticals, Aurobindo Pharmaceuticals
Published by A2Z Market Research
Posted on August 30, 2021
The global Rosuvastatin market is expected to grow at a CAGR of 3.7% in terms of revenue over the forecast period from 2021 to 2027, owing to several variables about which Research Informatic provides detailed insights and projections in the global Rosuvastatin market research.
Rising population across the globe, increase in the prevalence of obesity, developing medical infrastructure, and awareness of harmful effects of obesity and related disease on human health are driving the global rosuvastatin market. Also, patient’s preference for non-surgical therapy is expected to boost the global rosuvastatin market. Rosuvastatin lowers bad cholesterol and fats (LDL, triglycerides, etc.) while raising good cholesterol levels in the blood. Raising good cholesterol levels and reducing bad cholesterol levels in the blood helps to minimize the risk of heart disease, stroke, and other cardiovascular problems. Also, the worldwide Rosuvastatin market is mainly restrained by strict government regulations and intellectual property rights.
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.
Rosuvastatin Market: Segmentation
The research study segments the global rosuvastatin market based on type, delivery mode, treatment, distribution channel, and application. The market has been categorized type purity 98.0%, purity 99.0%, and others. The market is further divided based on delivery mode into parenteral, oral, and others. Based on treatment the global rosuvastatin market is segmented into stroke, obesity, treatment in pancreatitis, and others. The report covers distribution channels namely, retail pharmacies/ drug stores, hospital pharmacies, online stores, and others. In terms of application, the global rosuvastatin market is segmented into tablets, capsules and others.
Rosuvastatin Market: Regional Synopsis
The research report analyzes market size and forecasts for five major regions namely North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America, from 2016 to 2027. North America holds the largest market share of the global rosuvastatin market. This is owing to the rising incidence of obesity, a preference for non-surgical therapy, increased healthcare awareness, and solid healthcare infrastructure in North America. The United Kingdom has the most obese population in Europe, followed by France, Germany, Poland, and other countries. The rosuvastatin market in Europe, is the second-largest market in the world. It is expected to develop at a considerable rate throughout the projected period, owing to an increase in the prevalence of obesity and a high preference for non-surgical therapy in the region, as well as an increase in the number of people seeking treatment. Due to the huge patient population pool, in the Asia Pacific region and expanding medical infrastructure, availability of generic businesses, and rivalry between leading market participants and generic companies in the region, is expected to boost the global rosuvastatin market.
The Rosuvastatin industry has a moderately fragmented competitive landscape, with the top companies accounting for the majority of revenue. Some of the key players in the global Rosuvastatin market include Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis), Lupin Ltd., Hetero Drugs Ltd., Biocon Ltd., Cadilla Pharmaceuticals, Aurobindo Pharmaceuticals, Apotex Inc., IPR Pharmaceuticals Inc., Watson Labs Inc., Torrent Pharmaceuticals Ltd., Althera and Teva Pharmaceuticals. The major players in the industry are investing in research and development to manufacture innovative products. For instance, on April 1st, 2021 Athera announced that it has received FDA approval for its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial hypercholesterolemia.
Global Rosuvastatin Market: SegmentationRosuvastatin Market, by Type
The global Rosuvastatin market is expected to grow at a CAGR of 3.7% in terms of revenue over the forecast period from 2021 to 2027, owing to several variables about which Research Informatic provides detailed insights and projections in the global Rosuvastatin market research.
Rising population across the globe, increase in the prevalence of obesity, developing medical infrastructure, and awareness of harmful effects of obesity and related disease on human health are driving the global rosuvastatin market. Also, patient’s preference for non-surgical therapy is expected to boost the global rosuvastatin market. Rosuvastatin lowers bad cholesterol and fats (LDL, triglycerides, etc.) while raising good cholesterol levels in the blood. Raising good cholesterol levels and reducing bad cholesterol levels in the blood helps to minimize the risk of heart disease, stroke, and other cardiovascular problems. Also, the worldwide Rosuvastatin market is mainly restrained by strict government regulations and intellectual property rights.
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.
Rosuvastatin Market: Segmentation
The research study segments the global rosuvastatin market based on type, delivery mode, treatment, distribution channel, and application. The market has been categorized type purity 98.0%, purity 99.0%, and others. The market is further divided based on delivery mode into parenteral, oral, and others. Based on treatment the global rosuvastatin market is segmented into stroke, obesity, treatment in pancreatitis, and others. The report covers distribution channels namely, retail pharmacies/ drug stores, hospital pharmacies, online stores, and others. In terms of application, the global rosuvastatin market is segmented into tablets, capsules and others.
Rosuvastatin Market: Regional Synopsis
The research report analyzes market size and forecasts for five major regions namely North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America, from 2016 to 2027. North America holds the largest market share of the global rosuvastatin market. This is owing to the rising incidence of obesity, a preference for non-surgical therapy, increased healthcare awareness, and solid healthcare infrastructure in North America. The United Kingdom has the most obese population in Europe, followed by France, Germany, Poland, and other countries. The rosuvastatin market in Europe, is the second-largest market in the world. It is expected to develop at a considerable rate throughout the projected period, owing to an increase in the prevalence of obesity and a high preference for non-surgical therapy in the region, as well as an increase in the number of people seeking treatment. Due to the huge patient population pool, in the Asia Pacific region and expanding medical infrastructure, availability of generic businesses, and rivalry between leading market participants and generic companies in the region, is expected to boost the global rosuvastatin market.
The Rosuvastatin industry has a moderately fragmented competitive landscape, with the top companies accounting for the majority of revenue. Some of the key players in the global Rosuvastatin market include Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis), Lupin Ltd., Hetero Drugs Ltd., Biocon Ltd., Cadilla Pharmaceuticals, Aurobindo Pharmaceuticals, Apotex Inc., IPR Pharmaceuticals Inc., Watson Labs Inc., Torrent Pharmaceuticals Ltd., Althera and Teva Pharmaceuticals. The major players in the industry are investing in research and development to manufacture innovative products. For instance, on April 1st, 2021 Athera announced that it has received FDA approval for its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial hypercholesterolemia.
Global Rosuvastatin Market: SegmentationRosuvastatin Market, by Type
